

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 December 2005 (15.12.2005)

PCT

(10) International Publication Number
WO 2005/118626 A2

(51) International Patent Classification⁷: **C07K 14/18**,
A61K 39/295, G01N 33/576, A61K 38/16

(21) International Application Number:
PCT/EP2005/052457

(22) International Filing Date: 30 May 2005 (30.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04012951.2 1 June 2004 (01.06.2004) EP
60/576,310 3 June 2004 (03.06.2004) US
04447239.7 28 October 2004 (28.10.2004) EP
60/622,782 29 October 2004 (29.10.2004) US
60/665,395 25 March 2005 (25.03.2005) US
05102441.2 25 March 2005 (25.03.2005) EP

(71) Applicants (for all designated States except US): **INNO-
GENETICS N.V.** [BE/BE]; Technologiepark 6, B-9052
Ghent (BE); **IDM PHARMA INC.** [US/US]; 5820 Nancy
Ridge Drive, Suite 100, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEPLA, Erik**
[BE/BE]; Burgstraat 58, B-9070 Desselbergen (BE);
BUYSE, Marie-Ange [BE/BE]; Burg. E. Ronsestraat 23,
B-9820 Merelbeke (BE); **LASTERS, Ignace** [BE/BE];
Bosmanslei 38, B-2018 Antwerpen (BE); **DESMET,
Johan** [BE/BE]; Lode De Boningelaan 12, B-8500
Kortrijk (BE); **MAERTENS, Geert** [BE/BE]; Zilverpar-
renstraat 64, B-8310 Brugge (BE); **BAKER, Denise**
[US/US]; 13635 Jannet Place, Poway, California 92064
(US); **CHESNUT, Robert W.** [US/US]; 1473 Kings
Cross Drive, Cardiff-by-the-Sea, California 92007 (US).

NEWMAN, Mark [US/US]; 6603A Santa Isabel Street,
Carlsbad, California 92009 (US); **SETTE, Alessandro**
[IT/US]; 5551 Linda Rosa Avenue, La Jolla, California
92037 (US); **SIDNEY, John** [US/US]; 4218 Corte de
la Siena, San Diego, California 92130 (US); **SOUTH-
WOOD, Scott** [US/US]; 10679 Strathmore Drive, San Jose,
California 92071 (US).

(74) Common Representative: **INNOGENETICS N.V.**; In-
dustriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDES FOR INDUCING A CTL AND/OR HTL RESPONSE TO HEPATITIS C VIRUS

(57) Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.



WO 2005/118626 A2